Basic Information
| LncRNA/CircRNA Name | XIST |
| Synonyms | NA |
| Region | GRCh38_X:73820651-73852753 |
| Ensemble | ENSG00000229807 |
| Refseq | NR_001564 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | cervical cancer |
| ICD-0-3 | C53 |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown |
| Sample | cervical cancer tissues, cell lines (GH329, Hela, Caski,C4-1 and Siha) |
| Expression Pattern | up-regulated |
| Function Description | XIST was extremely overexpressed in cervical cancer tissues and cell lines. Kaplan Meier method was then applied to analyze the correlation between XIST expression and overall survival of cervical cancer patients. Cellproliferation was significantly suppressed by XIST knockdown. Apoptosis rate of XIST-silenced CC cells was obviously increased. XIST facilitated cellproliferation and inhibited cell apoptosis in cervical cancer. Additionally, the results of mechanistic experiments indicated that XIST upregulated Fus through competitively binding with miR-200a. Finally, rescue assays were conducted to demonstrate the regulatory function of XIST-miR-200a-Fus axis in cervical cancer progression. Collectively, XIST served as a ceRNA in cervical cancer progression through modulating miR-200a/Fus axis. |
| Pubmed ID | 29909347 |
| Year | 2018 |
| Title | LncRNA XIST Accelerates Cervical Cancer Progression via Upregulating Fus Through Competitively Binding With miR-200a |
External Links
| Links for XIST | GenBank HGNC NONCODE |
| Links for cervical cancer | OMIM COSMIC |